Invesco Ltd. Boosts Holdings in BioLife Solutions, Inc. (NASDAQ:BLFS)

Invesco Ltd. lifted its stake in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 1.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,239,469 shares of the medical equipment provider’s stock after acquiring an additional 36,176 shares during the period. Invesco Ltd. owned 6.98% of BioLife Solutions worth $84,097,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. D.A. Davidson & CO. grew its stake in shares of BioLife Solutions by 1.3% during the 4th quarter. D.A. Davidson & CO. now owns 41,179 shares of the medical equipment provider’s stock valued at $1,069,000 after buying an additional 519 shares during the period. Stifel Financial Corp grew its position in BioLife Solutions by 5.4% during the third quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock valued at $325,000 after acquiring an additional 670 shares during the period. 1620 Investment Advisors Inc. increased its stake in BioLife Solutions by 41.7% during the fourth quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider’s stock worth $60,000 after acquiring an additional 675 shares during the last quarter. Smartleaf Asset Management LLC raised its holdings in shares of BioLife Solutions by 27.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 4,469 shares of the medical equipment provider’s stock worth $117,000 after purchasing an additional 950 shares during the period. Finally, Steward Partners Investment Advisory LLC acquired a new position in shares of BioLife Solutions in the 4th quarter valued at about $26,000. 93.24% of the stock is owned by institutional investors and hedge funds.

BioLife Solutions Trading Up 4.3 %

Shares of BLFS opened at $21.90 on Monday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. BioLife Solutions, Inc. has a one year low of $14.84 and a one year high of $29.55. The stock has a 50-day moving average price of $25.04 and a 200 day moving average price of $25.35. The company has a market capitalization of $1.03 billion, a P/E ratio of -20.66 and a beta of 1.93.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.32. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. The business had revenue of $22.71 million during the quarter, compared to analyst estimates of $21.73 million. During the same quarter in the previous year, the firm earned ($0.21) earnings per share. Sell-side analysts forecast that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Sarah Aebersold sold 5,771 shares of the company’s stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $22.66, for a total transaction of $130,770.86. Following the sale, the insider now directly owns 80,094 shares of the company’s stock, valued at approximately $1,814,930.04. This represents a 6.72 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Aby J. Mathew sold 1,597 shares of BioLife Solutions stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $25.00, for a total transaction of $39,925.00. Following the completion of the transaction, the executive vice president now directly owns 260,601 shares of the company’s stock, valued at approximately $6,515,025. This represents a 0.61 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 72,127 shares of company stock worth $1,676,533. Corporate insiders own 2.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Northland Securities boosted their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 8th. HC Wainwright upped their price target on shares of BioLife Solutions from $27.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday, March 6th. StockNews.com raised BioLife Solutions from a “sell” rating to a “hold” rating in a research report on Tuesday, April 8th. Finally, Benchmark reiterated a “buy” rating and issued a $30.00 target price on shares of BioLife Solutions in a research note on Thursday, December 19th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.17.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.